The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

A new AAN position statement outlines guidelines for switching from branded biologics to biosimilars, while preserving clinical autonomy for physicians.

The AAP released its 2026 childhood immunization schedule, maintaining routine vaccine recommendations for several diseases despite revised CDC guidelines.

Midlife influenza immunization is not associated with an altered risk for Parkinson disease later in life, according to a ...

The FDA extended the duration of use of Nexplanon for pregnancy prevention in women of reproductive potential for up to 5 years.

Increased p-Tau181 levels may be associated with neurological manifestations of N-PASC consistent with central damage.

Common blood biomarkers, like those reflecting inflammatory, vascular, metabolic, and neurodegenerative processes, can predict multimorbidity.

Health officials are struggling to contain two growing measles outbreaks in the US, as new cases continue to climb.

Low-sodium oxybate reduces 24-hour sleep duration and daytime napping in adults with idiopathic hypersomnia, according to a phase 3 trial analysis.

As ACA subsidies end, the Trump administration floats a potential replacement that relies on a health savings account structure.

Valneva has made the decision to withdraw the Biologics License Application for its chikungunya vaccine Ixchiq®.

The HHS announces plans to reopen investigations and study the potential impact cellphones have on neurologic health.